CA2270867A1 - Antagonistes du facteur de croissance hepatocytaire - Google Patents

Antagonistes du facteur de croissance hepatocytaire Download PDF

Info

Publication number
CA2270867A1
CA2270867A1 CA002270867A CA2270867A CA2270867A1 CA 2270867 A1 CA2270867 A1 CA 2270867A1 CA 002270867 A CA002270867 A CA 002270867A CA 2270867 A CA2270867 A CA 2270867A CA 2270867 A1 CA2270867 A1 CA 2270867A1
Authority
CA
Canada
Prior art keywords
hgf
cells
test compound
antagonist
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002270867A
Other languages
English (en)
Inventor
David Patrick Brooks
Nicholas James Laping
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2270867A1 publication Critical patent/CA2270867A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une thérapie permettant de traiter chez l'homme une affection rénale chronique. Cette thérapie consiste à administrer à l'homme un antagoniste du facteur de croissance hépatocytaire.
CA002270867A 1996-11-05 1997-11-03 Antagonistes du facteur de croissance hepatocytaire Abandoned CA2270867A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3034296P 1996-11-05 1996-11-05
US60/030,342 1996-11-05
PCT/US1997/019891 WO1998019696A1 (fr) 1996-11-05 1997-11-03 Antagonistes du facteur de croissance hepatocytaire

Publications (1)

Publication Number Publication Date
CA2270867A1 true CA2270867A1 (fr) 1998-05-14

Family

ID=21853771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002270867A Abandoned CA2270867A1 (fr) 1996-11-05 1997-11-03 Antagonistes du facteur de croissance hepatocytaire

Country Status (4)

Country Link
EP (1) EP0941111A4 (fr)
JP (1) JP2001505995A (fr)
CA (1) CA2270867A1 (fr)
WO (1) WO1998019696A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1598801A (en) 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
KR101259655B1 (ko) 2005-04-15 2013-04-30 제넨테크, 인크. Ｈｇｆ 베타 사슬 변이체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571387B1 (fr) * 1990-09-14 2003-12-17 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Antagoniste de facteur de croissance d'hepatocytes competitif non mitogene
ES2181689T3 (es) * 1992-05-18 2003-03-01 Genentech Inc Variantes del factor de crecimiento de hepatocitos.
AU675968B2 (en) * 1992-09-18 1997-02-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A method of preventing tumor metastasis
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies

Also Published As

Publication number Publication date
EP0941111A1 (fr) 1999-09-15
JP2001505995A (ja) 2001-05-08
EP0941111A4 (fr) 2000-09-27
WO1998019696A1 (fr) 1998-05-14

Similar Documents

Publication Publication Date Title
Li et al. Hepatocyte growth factor and hepatocyte growth factor receptor in the lacrimal gland, tears, and cornea.
US7566741B2 (en) Methods of inhibiting osteoclast activity
CA2220036A1 (fr) Recepteur de neuropeptides humain
JP2001520039A (ja) ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２
Blanc et al. Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor alpha, and human serum
JP2002513037A (ja) Ｆｉｚｚタンパク質
AU6405499A (en) Artemin, a novel neurotrophic factor
CA2220123A1 (fr) Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine
EP1207873B1 (fr) Procedes d'inhibition de l'activite des osteoclastes
Konishi et al. Insulin-like growth factor II promotes in vitro cholinergic development of mouse septal neurons: comparison with the effects of insulin-like growth factor I
JP4405916B2 (ja) Ｆａｓペプチド模倣体およびその使用
WO2002039118A1 (fr) Procedes de criblage de mimetiques morphogenetiques osseux
CA2270867A1 (fr) Antagonistes du facteur de croissance hepatocytaire
Harris et al. Hepatocyte growth factor stimulates phosphoinositide hydrolysis and mitogenesis in cultured renal epithelial cells
US6682739B1 (en) Methods of inhibiting osteoclastogenesis
US5644026A (en) Epitaxin, a cell motility factor
JP2003113111A (ja) 糖尿病治療用医薬
WO2001008699A1 (fr) Methodes d'inhibition de l'osteoclastogenese
US20080027020A1 (en) Human Neuropeptide Receptor
US8580732B2 (en) Peptide therapy for hyperglycemia
RU2197262C2 (ru) Лиганд notch
US20240238437A1 (en) Therapeutics directed against coronavirus
US20100210520A9 (en) Regulation of function of angiopoietin
WO1996036709A1 (fr) Facteur de croissance transformant alpha hii
Hefti et al. Promotion of neuronal survival in vitro by thermal proteins and poly (dicar☐ ylic) amino acids

Legal Events

Date Code Title Description
FZDE Dead